Contemporary hypertrophic cardiomyopathy (HCM) family screening includes clinical evaluation and genetic testing (GT). This screening strategy requires the identification of a pathogenic mutation in the proband. Our aim was to examine the results of this HCM screening strategy.
H
ypertrophic cardiomyopathy (HCM) is the most common inherited cardiovascular disease with a prevalence of 1:500 to 1:200. 1 It is mainly transmitted in an autosomal dominant pattern, and the primary presentation may be sudden cardiac death (SCD). 2 Guidelines have encouraged family screening by electrocardiography and echocardiography since 2003. [2] [3] [4] The latest European guidelines recommend to include genetic testing (GT) in the screening strategy. 2 However, in several countries, the routine use of GT is hampered by insufficient healthcare insurance coverage. In The Netherlands, GT in HCM is covered by the national basic healthcare plan, and, therefore, can be routinely used for family screening. This strategy requires the identification of a pathogenic mutation in the proband, which is fulfilled in 40% to 60% of cases. 2 Genotype-positive (G+) relatives and relatives without GT are advised to undergo repeated cardiac evaluation. Genotype-negative (G−) relatives can be discharged. 2 Data regarding results of HCM screening including GT are scarce. 5, 6 The aim of this study was to examine the results of contemporary family screening in HCM, using GT and repeated cardiac evaluation.
METHODS

Study Design and Population
This retrospective cohort study included 777 relatives from 209 unrelated probands with HCM who visited the cardiogenetic outpatient clinic of the Erasmus Medical Center for screening purposes between 1985 and 2016. A median of 1 (interquartile range [IQR], 1-2) relative per proband was screened with a range of 1 to 17 relatives per proband. Relatives who presented symptomatically were excluded from the study. Relatives who were screened in another center and subsequently referred to our center were included. Families with HCM caused by Anderson-Fabry disease, Danon disease, Noonan syndrome, or amyloidosis were excluded. The study conforms to the principles of the Declaration of Helsinki. Subjects gave informed consent for inclusion in the Erasmus MC Inherited Cardiomyopathy Registry, and local institutional review board approval was obtained. The data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure. Requests for collaboration will be handled on an individual basis.
Genetic Analysis and Family Screening
Genetic counseling and testing was offered to all probands with HCM. Before the year 2012, genetic analysis consisted of direct sequencing of all coding intron-exon boundaries of the following genes: MYBPC3, MYH7, MYL2, MYL3, TNNT2, TNNI3, CSRP3, TCAP, TPM1, ACTC1, and TNNC1. From the year 2012, next-generation sequencing covering 48 cardiomyopathy-associated genes was used. Classification of variants was done at time of initial testing. Variants were interpreted using a protocol adapted from the American College of Medical Genetics and Genomics recommendations 7 and classified into 5 categories: (1) benign, (2) likely benign, (3) uncertain significance, (4) likely pathogenic, and (5) pathogenic. The potential pathogenicity of variants was assessed using Alamut Visual software (Interactive Biosoftware, Rouen, France), which integrates data from several large-scale population studies, evolutionary conservation of nucleotides and amino acids, in silico missense predictions (Align GVGD, Sorting Intolerant From Tolerant, MutationTaster, and PolyPhen-2), and splicing prediction modules (SpliceSiteFinder-like, MaxEntScan, NNSPLICE, GeneSplicer, and Human Splicing Finder). The criteria for classification of variants included the allele frequency in the Single Nucleotide Polymorphism Database/Exome Sequencing Project/The Exome Aggregation Consortium/Genome of the Netherlands (cutoff minor allele frequency 1% in at least 300
CLINICAL PERSPECTIVE
In hypertrophic cardiomyopathy (HCM) family screening, guidelines recommend repeated clinical evaluations from 10 to 12 years of age until advanced age. The latest European guidelines recommend to include genetic testing (GT) in the screening strategy. GT allows the identification of genotype-positive relatives without HCM and the reassurance and discharge of genotype-negative relatives. We retrospectively analyzed the results of this contemporary family screening strategy in 777 relatives of 209 probands who were evaluated at our cardiogenetic outpatient clinic where cardiac evaluation and genetic counseling and testing are offered simultaneously. After performing GT in 94% of the probands and 80% of the relatives, we were able to reassure 356 (46%) genotype-negative relatives, thereby significantly reducing the number of clinical screening visits. First cardiac evaluation in genotype-positive relatives (n=264) and relatives without GT (n=157) revealed HCM in 37% and 17%, respectively. During follow-up, cardiac mortality among relatives with HCM was low (0.3% per year) reflecting early disease stages. One genotype-positive relative without HCM died suddenly, and a long-QT mutation was identified postmortem. During 7 years follow-up, 16% of the relatives without HCM at first evaluation developed subtle HCM. The findings of the current study are important for the practicing clinician because they demonstrate the impact of GT on the HCM clinical screening process, and they show current challenges associated with GT in families with HCM. Moreover, evaluating the HCM prevalence at first evaluation and after repeated evaluations in adults and children and reporting the prognosis of relatives with and without HCM helps to determine the preferred clinical screening strategy.
ethnically matched control alleles equals benign), predicted effects on splicing, the in silico prediction of effect on the protein, and previously described links to disease. Furthermore, segregation analysis in families with more affected individuals and information considering presence in Human Gene Mutation Database Professional 2017.3 (Qiagen) is taken into account. Variant reclassifications during follow-up were registered, and variant classification as assessed at the end of follow-up was used for the analyses. Patients with a reclassified variant were informed about the reclassification and if applicable, about the indication for renewed evaluation. Patients were considered G+ when the mutation was classified as likely pathogenic or pathogenic (classes IV and V). First-degree relatives were informed by means of a family letter provided by the proband about the presence of HCM in the family including the indication for cardiac evaluation and if applicable, about the possibility of GT. GT was offered to relatives of probands with likely pathogenic or pathogenic variants and to relatives of probands without pathogenic mutations only in case HCM was revealed in the relative during cardiac screening. Based on this family letter, relatives with interest for screening were referred to the clinical geneticist by their general practitioner for counseling. G+ relatives and relatives who refused GT were referred for cardiac evaluation. G− relatives did not routinely undergo cardiac evaluation. Cardiac evaluation <10 years of age or GT before adulthood was offered in families with severe HCM in childhood, when cardiac symptoms were present or severe anxiety among parents existed. Cardiac evaluation was repeated every 2 to 4 years in phenotype-negative children and every 3 to 5 years in phenotype-negative adults. Genetic and cardiac screening was extended after identification of a G+ relative or HCM diagnosis in a relative (cascade screening).
Cardiac Evaluation
Cardiac evaluation included medical history, clinical examination, electrocardiography, and echocardiography. Cardiac symptoms were defined as ≥1 of the following: (1) typical or atypical angina (with disregard of nonanginal chest pain), (2) New York Heart Association functional class ≥2, or (3) a history of cardiac syncope. The diagnosis of HCM in relatives was based on a maximal wall thickness ≥13 mm or z score >2, unexplained by loading conditions. 2 Maximal wall thickness, left atrial size, left ventricular (LV) end-diastolic diameter, and LV outflow tract gradient at rest and during provocation were measured, according to the guidelines. 8 LV outflow tract gradient was calculated with the Bernoulli equation and LV outflow tract obstruction defined as a gradient ≥30 mm Hg at rest or during provocation. Systolic dysfunction was visually assessed and defined as mildly reduced, moderately reduced, or poor function. Diastolic dysfunction was defined as abnormal relaxation, pseudonormal filling, or restrictive filling, 9 based on the Doppler mitral inflow pattern parameters, including early (E) and late (A) LV filling velocities, E/A ratio, and tissue Doppler imaging-derived septal early diastolic velocities (e′).
Follow-Up and Outcome Measures
Follow-up data were obtained in July 2017 and were available in 99% of cases. Mortality was retrieved from the civil service register and cause of death from the medical chart or the general practitioner. Survival of the Dutch general population was obtained from the Central Agency for Statistics. 10 Cardiac mortality was defined as the combined end point of SCD, appropriate implantable cardioverter defibrillator (ICD) shock, and heart failure-related death (including cardiac transplantation). SCD was defined as instantaneous death in individuals who were previously in a stable condition or successful resuscitation after cardiac arrest. Appropriate ICD shock was defined as shock or antitachycardia pacing for ventricular fibrillation or ventricular tachycardia >200 per minute. Septal reduction therapy and ICD implantation for primary or secondary prevention of SCD were registered.
Statistical Analysis
Calculations were performed using SPSS 21 (IBM, Armonk, New York) and R Statistical Software, version 3.4.1, using packages nlme, lme4, and survival. Normally distributed continuous data are expressed as mean±SD and non-normally distributed data as median followed by IQR. Relationship to the patient was categorized into sibling, child, parent, and other, and the overall P value of this categorical variable was examined. To compare baseline characteristics between G+ relatives and relatives without GT, and between subjects with and without HCM at initial evaluation, generalized linear mixed models were used with random intercepts for family to account for family relatedness. For covariates with suspicion of collinearity, we screened for multicollinearity and ran the multivariate model twice. Fisher exact test was used in case of a zero cell count in either of the groups. For comparison of consecutive echocardiographic data, the paired t test was used and the Wilcoxon signed-rank test in case of nonnormally distributed data. Survival analyses were performed using the jackknife version of the Cox proportional hazards model to account for correlations caused by family relatedness. Results are presented with hazard ratio (HR) and 95% confidence interval (CI). All analyses were 2 sided; P values <0.05 were considered significant.
RESULTS
Genetic Testing
Figure 1 presents a flowchart of the results of GT in probands and relatives. GT was performed in 196 (94%) probands: 149 (76%) were G+, 33 (17%) had a variant with uncertain significance, and 14 (7%) were G−. GT was not performed in 13 (6%) probands because of premature death in 7 and refusal in 6. Figure 2A presents the affected genes in G+ probands. A complex genotype was present in 8 (5%), including 4 homozygous, 2 digenic, and 2 compound heterozygous mutations. During follow-up, the following 3 (2%) pathogenic mutations were reclassified into variants with uncertain significance after data sharing between different centers in The Netherlands: (1) CALR3 gene mutation c.564delT, (2) ABCC9 gene mutation c.4537G>A, and (3) MYPN gene mutation c.59A>G. An overview of pathogenic mutations and complex genotypes is provided in Tables I and II in the Data Supplement, respectively.
In the 47 (24%) probands without an identified pathogenic mutation, ≥8 sarcomeric genes were tested, and next-generation sequencing was performed in 34 (72%). In 24 (12%) probands without an identified pathogenic mutation, there was no family history of HCM. GT was performed in 620 (80%) relatives: 264 (43%) were G+, and 356 (57%) were G−. Figure 2B presents the affected genes in G+ relatives. A complex genotype was found in 6 (2%): 3 digenic and 3 homozygous mutations. GT was not performed in 157 relatives because of the following reasons: (1) G− proband (n=78; 50%), (2) refusal of GT, despite the presence of a pathogenic mutation in the proband (n=35; 22%), (3) GT not offered because of <18 years of age (n=25; 16%), and (4) no GT performed in the proband (n=19; 12%). Relatives without GT included 39 (25%) relatives who related to probands without an identified pathogenic mutation and no family history of HCM. Relatives who refused GT had a mean age of 29±11 years at the time of evaluation.
First Cardiac Screening
Cardiac screening was performed in 421 relatives: 264 G+ relatives (age, 41±18 years; 46% male) and 157 relatives without GT (age, 30±17 years; 48% male; Table 1 ). A small proportion of male and female relatives had cardiac symptoms (6% versus 11%; P=0.09). At first evaluation, HCM was diagnosed in 126 (30%) relatives: 98 (37%) G+ and 28 (17%) relatives without GT (P<0.001). Mean age at HCM diagnosis was 44±16 (range, 1-75) years, and 57% were male. Maximal wall thickness was ≥20 mm in 11 (9%) and ≥30 mm in none. Four (6%) had LV outflow tract obstruction, and 41 (40%) had diastolic dysfunction. One (0.2%) relative with a nonfounder MYBPC3 mutation had end-stage HCM, and another (with a digenic mutation) had noncompaction cardiomyopathy.
Among G+ relatives, the HCM prevalence was higher in nonfounder MYBPC3 mutation carriers than in Dutch founder MYBPC3 mutation carriers (49% versus 35%; P=0.04), despite similar age (43±17 versus 41±18 years; P=0.56). In 16 (57%) relatives with HCM, extensive GT in the proband failed to identify a pathogenic mutation. As presented in Figure 3 , the HCM prevalence increased with advancing age. In 41 children who were screened <12 years, 6 (15%) had HCM. All 6 children were asymptomatic; 5 had a cardiac murmur and 3 had a malignant family history of HCM.
Predictors of HCM During First Screening
Characteristics of relatives diagnosed with HCM versus those without HCM are summarized in Table 2 . Relatives diagnosed with HCM were more likely G+, were older at time of screening (44±16 versus 34±18 years; P<0.001), more likely male, more frequently symptomatic, related to probands with a younger age at diagnosis (37±17 versus 41±18 years; P=0.045), and were differently related to the proband (eg, sibling, child, parent, or other). Multivariate analysis demonstrates that G+ status (adjusted odds ratio, 4.23; 95% CI, 2.88-5.58; P<0.001), male sex (adjusted odds ratio, 2.13; 95% CI, 1.51-2.76; P=0.02), proband age at diagnosis (adjusted odds ratio, 0.98; 95% CI, 0.96-0.99; P=0.02), and age at time of screening (adjusted odds ratio, 1.04; 95% CI, 1.02-1.06; P<0.001) were independent predictors of HCM diagnosis. Symptomatic status lost significance in the multivariate analysis. The results of the multivariable model did not differ with inclusion of relation to the proband, and age had a more significant effect in the models than relation to the proband.
Clinical Outcome of Relatives With HCM
Mortality and interventions are presented in Table 3 . Relatives with HCM at baseline were followed for a median of 9 (IQR, 6-12) years. Annual all-cause and cardiac mortality was 0.7% and 0.3%, respectively. Cardiac mortality occurred in 7 (7%) relatives with HCM (all were G+) and included 3 cardiac transplants, 3 SCDs, and 1 appropriate ICD shock. There was no difference in either all-cause or cardiac mortality between Dutch founder MYBPC3 and nonfounder MYBPC3 mutation carriers (P=0.7 and P=0.6, respectively). Septal reduction therapy was performed in 8 (6%) relatives with HCM. ICDs for the primary prevention of SCD were implanted in 12 (12%) G+/HCM+ and 4 (14%) HCM+ relatives without GT (P=0.9). There was 1 appropriate ICD shock in a G+/HCM+ relative 3 years after implantation.
Echocardiographic follow-up with a median of 6.6 (IQR, 3.2-10.8) years was available in 103 (82%) relatives with HCM. LV end-diastolic diameter decreased (47±5 to 44±4 mm; P=0.006), and presence of diastolic dysfunction (40%-68%; P=0.003) and systolic dysfunction (1%-17%; P=0.001) increased. Seven (6%) patients developed end-stage HCM. Maximal wall thickness was overall stable (16±3 to 16±3 mm; P=0.54). 
Clinical Outcome of Relatives Without HCM
Relatives without HCM at baseline were followed for a median of 8 (IQR, 3-11) years. Annual all-cause mortality was 0.1%. Annual cardiac mortality in G+/ HCM− subjects was 0.06% (1 SCD event) and 0% in HCM− relatives without GT (Table 3) . SCD occurred in a 21-year-old nonfounder (c.1624+1G>A, p.?) MYB-PC3 mutation carrier. Autopsy confirmed the absence of HCM. Postmortem analysis revealed a pathogenic mutation (c.1708G>T, p.Ala570Ser) in the KCNH2 gene associated with long-QT syndrome. The ECG demonstrated no evidence of long QT, and there was no family history of long-QT syndrome. Two (1%) G+/HCM− subjects received an ICD for primary prevention; 1 had symptomatic nonsustained ventricular tachycardia, and the other, a troponin T mutation and family history of SCD. During a median 3-year (IQR, 2-11) follow-up, there were no appropriate ICD shocks and 1 inappropriate ICD shock because of lead failure.
Echocardiographic follow-up was available in 178 relatives without HCM (age, 32±19 years; 46% male; 65% G+). During a median 7-year (IQR, 4-10) followup, HCM developed in 29 (16%) relatives at the mean age of 40±20 (range, 9-77) years. The majority, 24 (83%), were G+ (20 MYBPC3 carriers, 2 MYH7 carriers, 1 MYL2 carrier, and 1 digenic MYBPC3/MYL2 carrier). G+ relatives were more likely to develop HCM than relatives without GT (HR, 2.44; 95% CI, 1.02-5.85; P=0.04; Figure 4A) ; however, not after adjusting for age (HR, 1.20; 95% CI, 0.46-3.14; P=0.71; Figure 4B ).
Adults (n=126; age, 41±14 years; 44% male; 77% G+) were followed for 6±4 years, and 19 (15%) developed HCM at mean age of 50±16 (range, 21-77) years. The majority, 15 (79%), were G+ (14 MYBPC3 carriers and 1 digenic MYBPC3/MYL2 carrier), and 68% were male. G+ adults were not more likely to develop HCM than adults without GT (HR, 1.44; 95% CI, 0.53-3.92; P=0.48). Maximal wall thickness increased from a median of 12 (IQR, 10-12) mm to a median of 14 (IQR, [13] [14] [15] Children (n=52; age, 10±5 years; 49% male; 36% G+) were followed for 14±8 years, and 10 (19%) developed HCM at mean age of 20±8 (range, 9-31) years. Conversion mostly occurred between 19 and 31 years of age (n=7; 70%) and did not occur between 12 and 18 years of age. The majority, 9 (90%), were G+ (6 MYBPC3 carriers, 2 MYH7 carriers, and 1 MYL2 carrier), and 70% were male. G+ children were not more likely to develop HCM than children without GT (HR, 3.26; 95% CI, 0.59-17.97; P=0.17). All-cause mortality, n (%) 13 ( (14) 4 (14) 5 (3) † 0
Primary prevention, n (%)
12 (12) 4 (14) 5 (3) 0 Secondary prevention, n (%)
Data are expressed as absolute n (%). P values are not presented because of low number of events. G+ indicates genotype positive; GT, genetic testing; HCM, hypertrophic cardiomyopathy; ICD, implantable cardioverter defibrillator; and SCD, sudden cardiac death.
*Two were successfully resuscitated. †Three (60%) received an ICD after HCM had developed during follow-up.
Survival of G− Relatives
All-cause mortality in G− relatives (age, 48±17 years; 45% male) was assessed 7.5±3.6 years after GT. Eighteen (5%) G− relatives died at the mean age of 69±15 (range, 49-88) years. As seen in Figure 5 , survival from all-cause mortality in G− relatives (97% at 5 years and 94% at 10 years), G+ relatives (99% at 5 years and 95% at 10 years), and relatives without GT (100% at 5 and 10 years) was similar. In multivariate cox regression analysis adjusting for age, sex, and family relatedness, survival from all-cause mortality in G− relatives was not significantly different from that in G+ relatives (adjusted HR, 0.92; 95% CI, 0.43-1.94; P=0.8).
There was an insufficient number of events in the relatives without GT (n=0) to compare survival between these relatives and G+ and G− relatives.
DISCUSSION
The key findings of this study on HCM family screening are as follows: (1) at first cardiac screening, HCM was diagnosed in 37% of G+ relatives and 17% of the relatives without GT (P<0.001); (2) G+ status, male sex, age at time of screening, and proband age at diagnosis were independent predictors of HCM diagnosis; (3) 16% of relatives without abnormalities at baseline developed HCM during 7 years of follow-up; and (4) survival in G− relatives, G+ relatives, and relatives without GT was good.
GT Facilitates HCM Screening
In the current study, 93% of probands and 80% of relatives underwent GT, which led to the reassurance of 356 G− relatives (46% of the total study population) and significantly reduced the number of clinical screening visits to the outpatient clinic. This supports previous studies that demonstrated the cost-effectiveness of family screening, including GT. 11, 12 As expected, the HCM prevalence was higher in G+ relatives because of the exclusion of G− relatives from cardiac evaluation.
The genetic yield in the probands was high (76%) in comparison with previous studies. 2, 13 This could partly be because of the large Dutch MYBPC3 founder population, 14 and partly because of a referral bias, because relatives from G+ families are informed about the confirmed heritability of HCM, and the HCM burden in G+ families is likely to be higher. 13 The rate of complex genotypes was relatively high (5%) in comparison with recent studies, which used contemporary variant classification methods. 15, 16 This might be related to the high prevalence of Dutch MYBPC3 founder mutations, the A, Kaplan-Meier curve demonstrating the cumulative HCM incidence during follow-up of relatives without HCM at baseline, stratified by genotype. B, Kaplan-Meier curve demonstrating the cumulative HCM incidence during follow-up of relatives without HCM at baseline, stratified by genotype and age. P values are calculated using the jackknife version of the Cox model to account for family relatedness. G+ indicates genotype positive; GT, genetic testing; and HCM, hypertrophic cardiomyopothy. Figure 5 . Survival of genotype-positive (G+) relatives, genotype-negative (G−) relatives, and relatives without genetic testing (GT). P value is calculated using the jackknife version of the multivariable Cox model to account for family relatedness, age, and sex. There was an insufficient number of events (n=0) in the relatives without GT to compare survival with G+ and G− relatives.
tertiary nature of our center, and the inclusion of children with more severe phenotypes.
HCM was found to be familial in families without an identified pathogenic mutation, despite extensive genotyping. This finding suggests that genetic causes are still unrecognized. This information can be useful for counseling purposes. Unfortunately, expanded gene panels using next-generation sequencing have offered limited additional pathogenic variants 17 and have increased the prevalence of variants with uncertain significance. 18 Potentially, whole-exome sequencing will have added value in the identification of novel HCM-causing genes, although this approach also has major challenges. 18 In 12% of the families, HCM was not familial, and no pathogenic mutation was identified. Relatives in these families may not have a Mendelian risk of disease, and so the utility of clinical screening may be impacted. 19 The inclusion of GT in family screening strategies allows the identification of this nonfamilial HCM subtype, which was reported to have later disease onset and better clinical outcome. 19, 20 It is important to be aware of the potential for variant reclassification. In this study, variants were classified according to the most recent knowledge. Reclassification occurred during follow-up after data sharing between different centers in The Netherlands. All G− relatives who were initially discharged from clinical evaluation should be informed about a reclassification and the indication for a renewed evaluation.
GT was refused by 6% of the relatives aged 29±11 years, likely because of socioeconomic consequences. The Dutch Medical Examination Act protects unaffected HCM mutation carriers for life insurance <€268.000 21 ; above this amount, carriers will have to disclose their HCM risk status, potentially resulting in an increased life insurance premium. 22, 23 Because healthcare insurance is obligatory in The Netherlands and covers the costs of GT, a lack of insurance coverage is not an issue. Other reasons for GT refusal include limited therapeutic implications. In the future, novel therapies 24 might increase the implications of GT.
Predictors of HCM During Screening
More male than female relatives were diagnosed with HCM-a finding that is in line with the described male predominance in HCM cohorts. 2, 25 Previous studies suggest that the underrepresentation of women may reflect reduced patient awareness regarding cardiovascular risk, referral bias, or clinician bias. 25 Referral bias in the current study is probably limited because all relatives presented in the context of HCM screening. It was left to the decision of the relative whether to accept the invitation for screening, which is influenced by many factors, including family and personal characteristics (symptomatic status, sex, race, and education). 26 Other possible explanations for male predominance in HCM may be related to genetic and endocrine factors. Studies in mice models of HCM-associated mutations have shown that male sex predisposes to an earlier onset of disease; however, the underlying pathophysiological mechanisms are not fully understood. 27, 28 HCM diagnosis was associated with advancing age-a feature that is in line with the described age-related penetrance of HCM. 29, 30 A younger age at diagnosis in the proband was associated with HCM in the relative. This illustrates the use of obtaining a family history and indicates a higher yield of screening in those families with more severe disease expression.
Clinical Outcome of Relatives With HCM and G+/HCM− Relatives
In relatives diagnosed with HCM during screening, cardiac mortality was low (0.3% per year) in comparison with the reported cardiac mortality in probands with HCM (1%-2% per year). 2 Because relatives are referred by familial evaluation instead of signs or symptoms, HCM in relatives is probably diagnosed in an earlier disease stage. 31 Lifestyle modifications, periodic SCD risk evaluation, and close clinical follow-up, resulting in ICD implantations, and timely referral for septal reduction therapies, might have led to a better clinical outcome. 32 Given the low event rate in HCM, larger numbers and longer follow-up are needed to really show an impact on clinical outcome. One G+/HCM− relative died suddenly, and a long-QT mutation was identified postmortem.
Family Screening Strategies Evaluated
Current guidelines 2,4,5 recommend cardiac evaluation from 10 to 12 years of age and repeat evaluation every 1 to 2 years until 18 to 21 years of age and every 2 to 5 years thereafter. Younger children can be screened in case of a severe family history, competitive sports participation, or when cardiac symptoms are present. 2 In this cohort, 6 of 41 (15%) children <12 years of age were diagnosed with HCM during clinical screening, which is more than expected and may be related to the tertiary nature of our center. Three of these cases did not have a severe family history, cardiac symptoms, or competed in sports, and so these cases would have been missed if current guidelines were followed. Simple cardiac auscultation would have raised suspicion because a cardiac murmur was present in almost all cases. The prevalence and prognosis of sarcomeric childhood HCM is currently unknown and requires investigation. 2 A multigenerational pedigree study demonstrated an increased mortality risk for untreated relatives aged 10 to 19 years with a 0.5 probability of truncating MYB-PC3 carriership. 33 This supports clinical evaluations from 10 years of age. Interestingly, our data demonstrate no conversion during adolescence but rather <12 and >18 years of age. This questions the need for more frequent evaluations during adolescence, 4 rather illustrates the need for earlier screening, that is, at the age of 8 years, and continued screening into adulthood, similar to the conclusions of Jensen et al. 2, 29 Whether or not to perform GT in children is disputable. Although we demonstrated in this study that GT has an impact on clinical screening strategies, the impact on management and lifestyle is limited because of the lack of prognostic value of genotype for disease onset and risk. Moreover, because of the potential social, emotional, psychosocial, educational, and financial consequences of GT and the advantage of integrating patients into medical decision-making, 34 we prefer to postpone GT until the legal age of 18 years. However, there are some situations in which the psychological or social benefits outweigh the risks of GT. For example, parents who cannot deal with the anxiety of not knowing might have a more negative impact on the child than would complying with the request for GT. In addition, early knowledge of carrier status might increase coping with the information. 34 Our HCM program makes decisions on a case-bycase basis after extensive counseling of the family and the child, including psychological support and taking all of the above considerations into account. We feel that screening frequencies should not be different in G+ children or children without GT because untested children may have a 50% probability of carriership. 33 In adults, we support intervals with a low frequency, for example, 5 yearly, as is advised by the 2011 American guidelines 4 because the HCM incidence was low and the development of hypertrophy slow.
Limitations
The efficiency of clinical screening is dependent on the uptake of GT in probands and relatives. The uptake of GT in the current study was high because in The Netherlands, GT is covered by the national basic healthcare insurance and because all probands were seen at our cardiogenetic outpatient clinic where cardiac evaluation and genetic counseling and testing are offered simultaneously. This limits generalizability of results to other countries with different financial and organizational approaches regarding GT in the HCM population. The high proportion of Dutch MYBPC3 founder mutation carriers limits representation of broader populations with HCM. The number of screened children was relatively small. Because of significant advances in DNAsequencing methodology during the past decade, there was no homogenous genotyping over the whole period. Because 12% of the study population was referred after HCM was diagnosed in another center, this has created a selection bias. Clinical phenotyping was not performed in G− relatives, limiting the ability to identify nonpenetrance or second variants, which may be an important caveat in some families.
Conclusion
HCM was identified in 30% of relatives at first screening, and 16% developed HCM during 7 years of repeated cardiac evaluation. GT led to a discharge from clinical follow-up in 46% of the study population. Survival in the relatives was good.
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